Hepatitis C Virus and Hepatocellular Carcinoma

  • Myron J. Tong
Conference paper


In the United States, infection by the hepatitis C virus (HCV) is a major cause of chronic liver disease, and is currently the leading cause for liver transplantation. Also, in many instances, chronic HCV infection may progress to hepatocellular carcinoma (HCC). The incidence of HCC is rising in the U.S., and probably will not reach its peak for another 10 or 20 years. During our earlier studies, we reported that after transfusion associated Hepatitis C in 131 patients, chronic hepatitis (CH), cirrhosis and HCC developed at a mean of 16 years, 20 years and 28 years after exposure, respectively. Also, we noted that patients who were transfused after the age of 50 years had a more rapidly progressive course in that CH, cirrhosis and HCC developed at a mean of 8.5 years, 10 years and 15 years respectively. A similar survey in 125 patients who used intravenous drugs (for 1 year or less) had similar mean progression rates as transfused patients (16 years for CH, 19 years for cirrhosis and 26 years for HCC). In our clinic population, HCC was mainly seen in patients with cirrhosis. In another longitudinal study of 112 patients who presented to our clinic with compensated cirrhosis showed that the annual incidence of decompensation was 4.4%, death from liver disease was 3.4% and development of HCC was 2.4%.


Chronic Hepatitis Interferon Therapy Cirrhosis Patient Transfuse Patient Characteristic Of91 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tong MJ, Lee SY, Hwang SJ, et al. Evidence for hepatitis C viral infection in patients with primary hepatocellular carcinoma. West J Med 1994;160:133–138.PubMedGoogle Scholar
  2. 2.
    Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463–1466.PubMedCrossRefGoogle Scholar
  3. 3.
    Tong MJ, El-Farra N. Clinical sequelae of hepatitis C acquired from injection drug use. West J Med 1996;164(5):399–404.PubMedGoogle Scholar
  4. 4.
    Hwang SJ, Tong MJ, Lai PP, et al. Evaluation of hepatitis B and C viral markers: clinical significance in asian and caucasian patients with hepatocellular carcinoma in the United States of America. J Gastroenterol Hepatol 1996;11(10):949–954.PubMedGoogle Scholar
  5. 5.
    Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parental exposure in the United States. Hepatology 1999;29(4):1311–1316.PubMedCrossRefGoogle Scholar
  6. 6.
    Hasan A, Danielian A, Tong MJ. A long-term follow-up of 150 chronic hepatitis C patients who were sustained virologic responders to interferon based therapy (in preparation).Google Scholar
  7. 7.
    Young H, Tong MJ. The clinical features of 100 patients with hepatitis C related hepato cellular carcinoma (in preparation).Google Scholar

Copyright information

© Springer Japan 2004

Authors and Affiliations

  • Myron J. Tong
    • 1
  1. 1.Liver CenterHuntington Medical Research InstitutesPasadenaUSA

Personalised recommendations